195 related articles for article (PubMed ID: 33558149)
21. CFTR Modulator Therapies in Pediatric Cystic Fibrosis: Focus on Ivacaftor.
Kramer EL; Clancy JP
Expert Opin Orphan Drugs; 2016 Oct; 4(10):1033-1042. PubMed ID: 28042521
[TBL] [Abstract][Full Text] [Related]
22. Improvement of lipid and lipoprotein profiles in children and adolescents with cystic fibrosis on CFTR modulator therapy.
Yuzyuk T; McDonald CM; Zuromski LM; De Biase I; Johnson L; Williams N; Meihls S; Asfour F
J Cyst Fibros; 2023 Nov; 22(6):1027-1035. PubMed ID: 37453889
[TBL] [Abstract][Full Text] [Related]
23. Chronic rhinosinusitis in the era of CFTR modulator therapy.
Stone RG; Short C; Davies JC; McNally P
J Cyst Fibros; 2024 Mar; 23(2):208-213. PubMed ID: 37690973
[TBL] [Abstract][Full Text] [Related]
24. Comparison of cystic fibrosis-related diabetes with type 1 diabetes based on a German/Austrian Pediatric Diabetes Registry.
Konrad K; Thon A; Fritsch M; Fröhlich-Reiterer E; Lilienthal E; Wudy SA; Holl RW;
Diabetes Care; 2013 Apr; 36(4):879-86. PubMed ID: 23238661
[TBL] [Abstract][Full Text] [Related]
25. Survival-Adjusted FEV1 and BMI Percentiles for Patients with Cystic Fibrosis before the Era of Triple CFTR Modulator Therapy in Germany.
Dittrich AS; Dumke M; Kapl F; Schneider P; Wege S; Gräber S; Stahl M; Herth FJ; Naehrlich L; Mall MA; Sommerburg O;
Respiration; 2023; 102(5):1. PubMed ID: 37062281
[TBL] [Abstract][Full Text] [Related]
26. Chronic rhinosinusitis in patients with cystic fibrosis-Current management and new treatments.
Johnson BJ; Choby GW; O'Brien EK
Laryngoscope Investig Otolaryngol; 2020 Jun; 5(3):368-374. PubMed ID: 32596478
[TBL] [Abstract][Full Text] [Related]
27. Beyond insulin: Unraveling the complex interplay of ER stress, oxidative damage, and CFTR modulation in CFRD.
Umashankar B; Eliasson L; Ooi CY; Kim KW; Shaw JAM; Waters SA
J Cyst Fibros; 2024 Jun; ():. PubMed ID: 38897882
[TBL] [Abstract][Full Text] [Related]
28. Effects of modulator therapies on endocrine complications in adults with cystic fibrosis: a narrative review.
Kumar S; Soldatos G; Teede HJ; Pallin M
Med J Aust; 2023 Nov; 219(10):496-502. PubMed ID: 37839059
[TBL] [Abstract][Full Text] [Related]
29. Physical Activity Levels in Individuals with Cystic Fibrosis-Related Diabetes.
Currie S; Greenwood K; Weber L; Khakee H; Legasto M; Tullis E; Wu K; Tsang A; Szego E; Mathur S
Physiother Can; 2017; 69(2):171-177. PubMed ID: 28539697
[No Abstract] [Full Text] [Related]
30. Letter to the editor: A contemporary assessment of CFTR modulator use and eligibility.
Rubin JL; Kreindler JL
J Cyst Fibros; 2024 Mar; 23(2):368-369. PubMed ID: 38438296
[No Abstract] [Full Text] [Related]
31. Pregnancy in women with cystic fibrosis and diabetes: An audit of outcomes at two tertiary obstetric hospitals in Australia in the pre-cystic fibrosis transmembrane conductance regulator modulator era.
Davidson SJ; France M; Callaway LK; Lust K; Chambers D; Hopkins P; Bell SC; Burr L; Keating R; Barrett HL
Obstet Med; 2023 Dec; 16(4):217-221. PubMed ID: 38074210
[TBL] [Abstract][Full Text] [Related]
32. Glycemic Variability and the Thickness of Retinal Layers in Cystic Fibrosis Patients with and without Cystic Fibrosis Related Diabetes.
Saegebrecht LS; Röhlig M; Schaub F; Ballmann M; Stachs O; Fischer DC
Curr Eye Res; 2024 Jul; 49(7):759-767. PubMed ID: 38557392
[TBL] [Abstract][Full Text] [Related]
33. A provider survey assessing fetal impact of CFTR modulator use in males with CF during assisted and unassisted reproduction and partner pregnancy.
Taylor-Cousar JL; Janney R; Middleton PG; Jain R; Nightingale J; West NE; Shteinberg M; Velez D; Kazmerski TM
J Cyst Fibros; 2024 May; 23(3):412-416. PubMed ID: 37953181
[TBL] [Abstract][Full Text] [Related]
34. Vitamin D for glycemic control following an acute pulmonary exacerbation: A secondary analysis of a multicenter, double-blind, randomized, placebo-controlled trial in adults with cystic fibrosis.
Sivapiromrat AK; Hunt WR; Alvarez JA; Ziegler TR; Tangpricha V
medRxiv; 2024 Mar; ():. PubMed ID: 38343807
[TBL] [Abstract][Full Text] [Related]
35. Practical aspects of diabetes technology use: Continuous glucose monitors, insulin pumps, and automated insulin delivery systems.
Marks BE; Williams KM; Sherwood JS; Putman MS
J Clin Transl Endocrinol; 2022 Mar; 27():100282. PubMed ID: 34917483
[TBL] [Abstract][Full Text] [Related]
36. Clinical Observations in Patients With Cystic Fibrosis-Related Diabetes and Self-Reported Ototoxicity Symptoms.
Nichols N; Rubenstein RC; Kelly A; Vachhani JJ; Echaluse MV; Garinis AC
Am J Audiol; 2023 Nov; 33(1):1-9. PubMed ID: 38016170
[TBL] [Abstract][Full Text] [Related]
37. Role of hyperglycemia in cystic fibrosis pulmonary exacerbations.
Merjaneh L; Sidhaye AR; Vu PT; Heltshe SL; Goss CH; Flume PA; Kelly A; Rosenfeld M
J Cyst Fibros; 2023 Sep; 22(5):868-874. PubMed ID: 37394317
[TBL] [Abstract][Full Text] [Related]
38. An Update in Cystic Fibrosis-Related Diabetes in Children and Adolescents.
Anton-Păduraru DT; Murgu AM; Donos MA; Trofin F; Azoicăi AN; Popovici P; Stana AB; Gheorghiescu I; Trandafir LM
Children (Basel); 2023 Nov; 10(12):. PubMed ID: 38136081
[TBL] [Abstract][Full Text] [Related]
39. Association between cystic fibrosis transmembrane regulator genotype and clinical outcomes, glucose homeostasis indices and CF-related diabetes risk in adults with CF.
Bélanger N; Bonhoure A; Kherani T; Boudreau V; Tremblay F; Lavoie A; Carricart M; Marwaha A; Rabasa-Lhoret R; Potter KJ
Genet Mol Biol; 2024; 47(1):e20230021. PubMed ID: 38558018
[TBL] [Abstract][Full Text] [Related]
40. Quality of dietary macronutrients is associated with glycemic outcomes in adults with cystic fibrosis.
Daley TC; Cousineau BA; Nesbeth PC; Ivie EA; Bellissimo MP; Easley KA; Vellanki P; Vos MB; Hunt WR; Stecenko AA; Ziegler TR; Alvarez JA
Front Nutr; 2023; 10():1158452. PubMed ID: 37799765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
